328 related articles for article (PubMed ID: 24721226)
1. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
[TBL] [Abstract][Full Text] [Related]
3. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Gillooly KM; Pulicicchio C; Pattoli MA; Cheng L; Skala S; Heimrich EM; McIntyre KW; Taylor TL; Kukral DW; Dudhgaonkar S; Nagar J; Banas D; Watterson SH; Tino JA; Fura A; Burke JR
PLoS One; 2017; 12(7):e0181782. PubMed ID: 28742141
[TBL] [Abstract][Full Text] [Related]
5. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.
Wang SP; Iwata S; Nakayamada S; Niiro H; Jabbarzadeh-Tabrizi S; Kondo M; Kubo S; Yoshikawa M; Tanaka Y
Rheumatology (Oxford); 2015 Aug; 54(8):1488-97. PubMed ID: 25724205
[TBL] [Abstract][Full Text] [Related]
6. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
Hartkamp LM; Fine JS; van Es IE; Tang MW; Smith M; Woods J; Narula S; DeMartino J; Tak PP; Reedquist KA
Ann Rheum Dis; 2015 Aug; 74(8):1603-11. PubMed ID: 24764451
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
[TBL] [Abstract][Full Text] [Related]
8. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
Zorn CN; Keck S; Hendriks RW; Leitges M; Freudenberg MA; Huber M
Cell Signal; 2009 Jan; 21(1):79-86. PubMed ID: 18848985
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
12. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes.
Brunner C; Avots A; Kreth HW; Serfling E; Schuster V
Immunobiology; 2002 Oct; 206(4):432-40. PubMed ID: 12437073
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase as a drug discovery target.
Pan Z
Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
[TBL] [Abstract][Full Text] [Related]
15. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
[TBL] [Abstract][Full Text] [Related]
16. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
[TBL] [Abstract][Full Text] [Related]
17. BTK Signaling in B Cell Differentiation and Autoimmunity.
Corneth OBJ; Klein Wolterink RGJ; Hendriks RW
Curr Top Microbiol Immunol; 2016; 393():67-105. PubMed ID: 26341110
[TBL] [Abstract][Full Text] [Related]
18. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
19. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
20. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
